Is IMRX or ARDX more profitable?

Immuneering has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Immuneering's return on equity of -31.93% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Ardelyx -13.58% -38.11% -11.85%

Does the media favor IMRX or ARDX?

In the previous week, Immuneering had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Immuneering and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Immuneering's score of 0.07 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IMCR or IMRX?

In the previous week, Immuneering had 2 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Immuneering and 3 mentions for Immunocore. Immunocore's average media sentiment score of 0.63 beat Immuneering's score of 0.07 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PURR or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% Immuneering N/A -31.93% -29.92%

Does the media refer more to PURR or IMRX?

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Hyperliquid Strategies and 5 mentions for Immuneering. Hyperliquid Strategies' average media sentiment score of 0.83 beat Immuneering's score of 0.07 indicating that Hyperliquid Strategies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperliquid Strategies 1 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is IMRX or KALV more profitable?

Immuneering's return on equity of -31.93% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% KalVista Pharmaceuticals N/A -341.44% -111.94%

Does the media prefer IMRX or KALV?

In the previous week, Immuneering had 1 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 5 mentions for Immuneering and 4 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.62 beat Immuneering's score of 0.07 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral KalVista Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, IMRX or MLTX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is IMRX or MLTX more profitable?

Immuneering's return on equity of -31.93% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media favor IMRX or MLTX?

In the previous week, Immuneering and Immuneering both had 5 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Immuneering's score of 0.07 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immuneering (IMRX) Competitors

$4.55 +0.27 (+6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$4.50 -0.04 (-0.99%)

As of 07:58 PM Eastern

Compare

IMRX vs. ARDX, IMCR, PURR, KALV, and MLTX

Should you buy Immuneering stock or one of its competitors? MarketBeat compares Immuneering with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuneering include Ardelyx (ARDX), Immunocore (IMCR), Hyperliquid Strategies (PURR), KalVista Pharmaceuticals (KALV), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.

How does Immuneering compare to Ardelyx?

Immuneering (NASDAQ:IMRX) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Immuneering presently has a consensus price target of $16.50, suggesting a potential upside of 262.64%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 189.67%. Given Immuneering's higher probable upside, research analysts clearly believe Immuneering is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Immuneering has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Ardelyx	$407.32M	3.29	-$61.60M	-$0.23	N/A

Immuneering has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Immuneering's return on equity of -31.93% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Ardelyx	-13.58%	-38.11%	-11.85%

Immuneering has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

67.7% of Immuneering shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 22.9% of Immuneering shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Immuneering had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Immuneering and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.93 beat Immuneering's score of 0.07 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immuneering and Ardelyx tied by winning 7 of the 14 factors compared between the two stocks.

How does Immuneering compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Immunocore has higher revenue and earnings than Immuneering. Immunocore is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	3.63	-$35.51M	-$0.55	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Immuneering has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
Immuneering	N/A	-31.93%	-29.92%

In the previous week, Immuneering had 2 more articles in the media than Immunocore. MarketBeat recorded 5 mentions for Immuneering and 3 mentions for Immunocore. Immunocore's average media sentiment score of 0.63 beat Immuneering's score of 0.07 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Immunocore has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Immunocore currently has a consensus price target of $56.71, indicating a potential upside of 97.96%. Immuneering has a consensus price target of $16.50, indicating a potential upside of 262.64%. Given Immuneering's stronger consensus rating and higher possible upside, analysts plainly believe Immuneering is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

84.5% of Immunocore shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 22.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immunocore beats Immuneering on 8 of the 14 factors compared between the two stocks.

How does Immuneering compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Immuneering (NASDAQ:IMRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Hyperliquid Strategies currently has a consensus price target of $9.25, indicating a potential downside of 10.80%. Immuneering has a consensus price target of $16.50, indicating a potential upside of 262.64%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Hyperliquid Strategies had 1 more articles in the media than Immuneering. MarketBeat recorded 6 mentions for Hyperliquid Strategies and 5 mentions for Immuneering. Hyperliquid Strategies' average media sentiment score of 0.83 beat Immuneering's score of 0.07 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperliquid Strategies	1 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Immuneering's return on equity of -31.93% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Immuneering	N/A	-31.93%	-29.92%

9.5% of Hyperliquid Strategies shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 8.5% of Hyperliquid Strategies shares are owned by insiders. Comparatively, 22.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hyperliquid Strategies has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,497.95	-$16.01M	-$7.37	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Hyperliquid Strategies has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Immuneering beats Hyperliquid Strategies on 9 of the 14 factors compared between the two stocks.

How does Immuneering compare to KalVista Pharmaceuticals?

Immuneering (NASDAQ:IMRX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, Immuneering had 1 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 5 mentions for Immuneering and 4 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 0.62 beat Immuneering's score of 0.07 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
KalVista Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.7% of Immuneering shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immuneering's return on equity of -31.93% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Immuneering has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Immuneering presently has a consensus target price of $16.50, indicating a potential upside of 262.64%. KalVista Pharmaceuticals has a consensus target price of $30.60, indicating a potential upside of 13.56%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts plainly believe Immuneering is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Immuneering has higher earnings, but lower revenue than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
KalVista Pharmaceuticals	$49.08M	29.23	-$109.52M	-$3.46	N/A

Summary

Immuneering beats KalVista Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Immuneering compare to MoonLake Immunotherapeutics?

Immuneering (NASDAQ:IMRX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immuneering has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

In the previous week, Immuneering and Immuneering both had 5 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Immuneering's score of 0.07 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Immuneering's return on equity of -31.93% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Immuneering currently has a consensus target price of $16.50, suggesting a potential upside of 262.64%. MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 30.52%. Given Immuneering's stronger consensus rating and higher possible upside, equities analysts clearly believe Immuneering is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Immuneering beats MoonLake Immunotherapeutics on 8 of the 12 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$276.90M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	N/A	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	1.35	6.63	9.84	6.72
Net Income	-$56.03M	$24.20M	$3.57B	$337.19M
7 Day Performance	-14.79%	-3.24%	-1.16%	0.48%
1 Month Performance	-15.27%	0.53%	3.85%	5.07%
1 Year Performance	132.14%	47.24%	27.40%	34.25%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.1754 of 5 stars	$4.55 +6.3%	$16.50 +262.6%	+128.9%	$276.90M	N/A	N/A	60	Analyst Forecast
ARDX Ardelyx	2.8968 of 5 stars	$5.51 -3.9%	$15.70 +185.2%	+43.4%	$1.49B	$427.68M	N/A	90
IMCR Immunocore	2.7641 of 5 stars	$28.75 -1.3%	$56.71 +97.2%	-23.5%	$1.48B	$412.81M	N/A	320	High Trading Volume
PURR Hyperliquid Strategies	1.4664 of 5 stars	$11.16 +2.7%	$9.25 -17.1%	N/A	$1.44B	$1M	N/A	N/A	Gap Up High Trading Volume
KALV KalVista Pharmaceuticals	2.5233 of 5 stars	$26.95 +0.0%	$30.60 +13.6%	+108.5%	$1.43B	$1.43M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. ARDX, IMCR, PURR, KALV, and MLTX

How does Immuneering compare to Ardelyx?

Summary

How does Immuneering compare to Immunocore?

Summary

How does Immuneering compare to Hyperliquid Strategies?

Summary

How does Immuneering compare to KalVista Pharmaceuticals?

Summary

How does Immuneering compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. ARDX, IMCR, PURR, KALV, and MLTX

How does Immuneering compare to Ardelyx?

Do analysts rate IMRX or ARDX?

Which has stronger earnings and valuation, IMRX or ARDX?

Is IMRX or ARDX more profitable?

Which has more volatility & risk, IMRX or ARDX?

Do institutionals & insiders have more ownership in IMRX or ARDX?

Does the media favor IMRX or ARDX?

Summary

How does Immuneering compare to Immunocore?

Which has stronger valuation & earnings, IMCR or IMRX?

Is IMCR or IMRX more profitable?

Does the media prefer IMCR or IMRX?

Which has more risk and volatility, IMCR or IMRX?

Do analysts prefer IMCR or IMRX?

Do institutionals & insiders believe in IMCR or IMRX?

Summary

How does Immuneering compare to Hyperliquid Strategies?

Do analysts rate PURR or IMRX?

Does the media refer more to PURR or IMRX?

Is PURR or IMRX more profitable?

Do institutionals and insiders believe in PURR or IMRX?

Which has preferable valuation & earnings, PURR or IMRX?

Which has more volatility and risk, PURR or IMRX?

Summary

How does Immuneering compare to KalVista Pharmaceuticals?

Does the media prefer IMRX or KALV?

Do institutionals & insiders believe in IMRX or KALV?

Is IMRX or KALV more profitable?

Which has more volatility & risk, IMRX or KALV?

Do analysts rate IMRX or KALV?

Which has stronger earnings and valuation, IMRX or KALV?

Summary

How does Immuneering compare to MoonLake Immunotherapeutics?

Do institutionals and insiders hold more shares of IMRX or MLTX?

Which has more risk & volatility, IMRX or MLTX?

Does the media favor IMRX or MLTX?

Which has higher earnings & valuation, IMRX or MLTX?

Is IMRX or MLTX more profitable?

Do analysts prefer IMRX or MLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools